Main clinical characteristics and outcome of our patients
| Patient | Medical history | BMI (kg/m2) | A1C (%) | Insulin naïve | BG at CIVII initiation (mg/dL) | Average BG on CIVII (mg/dL) | Duration on CIVII (hours) | Average insulin drip rate (units/hour) | Highest insulin drip rate (units/hour) | Steroid use during CIVII | Initial regimen after CIVII D/C | Death |
| 1 | Type 2 diabetes, HTN, obesity | 37.8 | 8.3 | Yes | 496 | 179 | 133 | 170 | 500 | Yes | Insulin glargine 175 units two times per day, HDSS | Yes |
| 2 | Type 2 diabetes, CAD, HTN, HLD, obesity | 40.3 | 7 | No | 352 | 199 | 79 | 182 | 500 | Yes | Insulin glargine 175 units two times per day, HDSS | Yes |
| 3 | Type 2 diabetes, HTN, obesity | 33.8 | 11.4 | Yes | 326 | 162 | 448* | 21 | 100 | No | Insulin glargine 80 units two times per day, HDSS | No |
| 4 | Type 2 diabetes, HLD, obesity | 34.8 | 9.8 | Yes | 390 | 177 | 207 | 29 | 100 | Yes | N/A | Yes |
*The duration on CIVII for patient 3 is represented as the total hours of two separate initiations during the same hospital stay.
BG, blood glucose; BMI, body mass index; CAD, coronary artery disease; CIVII, continuous intravenous insulin infusion; D/C, discontinued; HDSS, high-dose sliding scale; HLD, hyperlipidemia; HTN, hypertension; N/A, not available.